Hormonal
Elevated circulating levels of branched-chain amino acids (Leu, Ile, Val) and aromatic amino acids (Phe, Tyr) are strongly associated with insulin resistance (HOMA-IR) in young, normoglycemic adults, with associations being significantly stronger in men and in women only when abdominally obese.
If you are young and healthy, high levels of certain amino acids in your blood may signal early insulin resistance, especially if you carry weight around your midsection. This is not a diagnosis of diabetes, but a signal to prioritize physical activity and metabolic health. The study suggests these markers are secondary to insulin resistance rather than the cause, so focusing on overall metabolic health (exercise, healthy fats) is more effective than restricting protein intake.
Branched-chain and aromatic amino acids, gluconeogenesis intermediates, ketone bodies, and fatty acid composition and saturation were associated with HOMA-IR (P < 0.0005 for 20 metabolite measures). Leu, Ile, Val, and Tyr displayed sex- and obesity-dependent interactions, with associations being significant for women only if they were abdominally obese.
Why this rating
Large population-based cohort (n=7,098), rigorous statistical adjustment, replication across two cohorts, but cross-sectional design limits causal inference.
Source
Metabolic Signatures of Insulin Resistance in 7,098 Young Adults
Peter Würtz et al. · Diabetes · 2012
DOI 10.2337/db11-1355
More from this paper
- Physical activity is inversely associated with insulin resistance and circulating metabolite levels, but these associations are largely attenuated when adjusting for HOMA-IR, suggesting physical activity improves insulin sensitivity directly rather than by lowering specific metabolite levels.Good
- Genetic variants that regulate circulating amino acid and lipid levels generally do not cause insulin resistance, suggesting that elevated amino acids are likely secondary markers of insulin resistance rather than causal drivers.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →